Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on March 9, 2010, at a price of £12.49 per share through the Company's Share Reward Plan. Each individual acquired 10 shares via a personal contribution (partnership element) and 10 shares via a company contribution (matching element). The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. S A Hussain, Mr. D Learmouth, Mr. D S Redfern, and Ms. C Thomas.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.49 per Ordinary share on March 9, 2010.
- Confirm the total number of shares acquired by each listed director (20 shares per person: 10 personal, 10 matched).
- Review the terms of the Company's Share Reward Plan to understand the matching mechanism.
- Note that this filing contains no financial performance metrics for the period.